Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823696 | 0.88 | PIK3CA (0.42) | PIK3CACREBBPMTORBRD4 | |
| SCHEMBL3765213 | 0.84 | PIK3CA (0.42) | PIK3CACREBBPMTORLCKMAP4K3 | |
| SCHEMBL7816565 | 0.83 | PIK3CA (0.38) | PIK3CACREBBPMTORKMT2A | |
| SCHEMBL859033 | 0.82 | PIK3CA (0.38) | PIK3CACREBBPMTORLCKMAP4K3 | |
| SCHEMBL856855 | 0.82 | PIK3CA (0.39) | PIK3CACREBBPMTORLCKMAP4K3 | |
| SCHEMBL856827 | 0.81 | PIK3CA (0.38) | PIK3CACREBBPMTORSYK | |
| SCHEMBL857892 | 0.80 | PIK3CA (0.38) | PIK3CACREBBPMTOR | |
| SCHEMBL859214 | 0.79 | PIK3CA (0.49) | PIK3CACREBBP | |
| SCHEMBL3760531 | 0.78 | PIK3CA (0.39) | PIK3CACREBBPMTORLCKMAP4K3 | |
| SCHEMBL855888 | 0.78 | PIK3CA (0.39) | PIK3CACREBBPMTORLCKMAP4K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010135568-A1 | BENZOXAZEPINES AS INHIBITORS OF MTOR AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |